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Background: Shark liver oil (SLOil) and fish oil (FOil), which are respectively rich in alkylglycerols (AKGs) and n-3
polyunsaturated fatty acids (PUFAs), are able to reduce the growth of some tumors and the burden of cachexia. It is
known that FOil is able to reduce proliferation rate and increase apoptotic cells and lipid peroxidation of tumor
cells efficiently. However, there are few reports revealing the influence of SLOil on these parameters. In the current
study, effects of FOil chronic supplementation on tumor growth and cachexia were taken as reference to compare
the results obtained with SLOil supplementation. Also, we evaluated if the association of SLOil and FOil was able to
promote additive effects.
Methods: Weanling male Wistar rats were divided into 4 groups: fed regular chow (C), supplemented (1 g/kg body
weight) with SLOil (CSLO), FOil (CFO) and both (CSLO + FO). After 8 weeks half of each group was inoculated with
Walker 256 cells originating new groups (W, WSLO, WFO and WSLO + FO). Biochemical parameters of cachexia,
tumor weight, hydroperoxide content, proliferation rate and percentage of apoptotic tumor cells were analysed.
Fatty acids and AKG composition of tumor and oils were obtained by high performance liquid chromatography
and gas chromatography – mass spectrometry, respectively. Statistical analysis was performed by unpaired t-test
and one-way ANOVA followed by a post hoc Tukey test.
Results: Fourteen days after inoculation, SLOil was able to restore cachexia parameters to control levels, similarly to
FOil. WSLO rats presented significantly lower tumor weight (40%), greater tumor cell apoptosis (~3-fold), decreased
tumor cell proliferation (35%), and higher tumor content of lipid hydroperoxides (40%) than observed in W rats, but
FOil showed more potent effects. Supplementation with SLOil + FOil did not promote additive effects. Additionally,
chromatographic results suggested a potential incorporation competition between the n-3 fatty acids and the AKGs
in the tumor cells’ membranes.
Conclusions: SLOil is another marine source of lipids with similar FOil anti-cachectic capacity. Furthermore, despite
being less potent than FOil, SLOil presented significant in vivo antitumor effects. These results suggest that the
chronic supplementation with SLOil may be adjuvant of the anti-cancer therapy.
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Cancer susceptibility is determined by genetic factors;
however, environmental factors seem to influence which
subjects genetically susceptible will be affected. In this
context, nutrition has been aroused as a main component
in such relation [1]. Nutrition has a central role in this
feature, because it can be applied as a preventive tool or
as a component of the anti-cancer therapy when the dis-
ease is already installed. Among several other nutrients,
lipids receive a special attention in such line of thinking.
Phospholipids and other lipids, incorporated into cell
membranes or other compartments, can have their
molecular composition altered depending on the lipid
nutrition profile of the subject. This fact justifies the
importance of studies investigating the repercussions
of different lipid nutritional supply on cancer progress.
One of the most common manifestations of cancer is
the development of cachexia syndrome, a chronic wasting
condition responsible for the loss of both adipose and
skeletal muscle tissues. At least 20% of the deaths among
cancer patients are due to cachexia [2]. This syndrome in-
volves immune-metabolic pathways, and so far, the mech-
anisms by which it happens remain not fully understood.
Western countries have a diet rich in saturated and n-6
polyunsaturated fatty acids (PUFAs). Such a diet is com-
monly low in n-3 PUFAs and vitamins C and E, which have
been associated with the development of some cancers.
Fish oil (FOil) is a source of long chain n-3 PUFAs, such
as eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA). These n-3 PUFAs have been shown to decrease
the risk for several cancers [3,4], the tumor growth [5-7],
and cancer cachexia [8,9] in both animal models [6,10,11]
and clinical trials [3,9,12]. The mechanisms by which
n-3 PUFAs cause such effects are not fully understood.
Noteworthy, the participation of increased lipid peroxida-
tion in tumor tissue [6,7], reduction of proinflammatory
cytokines and chemical mediators that induce cell prolifer-
ation [7,13,14], and promotion of tumor cell apoptosis
[7,11,15,16] have been reported.
Another marine compound that contains n-3 PUFAs
is shark liver oil (SLOil). Besides the n-3 PUFAs, SLOil
also presents alkylglycerols (AKGs) in its composition.
These compounds are constituted by glycerol linked to
the hydrocarbon tail in the sn-1 position by ether bonds.
AKGs can be associated to fatty acids by ester bonds in the
sn-2 and sn-3 positions, constituting alkyldiacylglycerol
molecules [17]. AKGs represent about 20% of the shark
liver oil lipid composition [18]. These ether lipids are found
in hematopoietic organs of mammals, especially in the bone
marrow and in human breast milk. SLOil seems to be
an immune system enhancer [19,20], and this effect is
attributed in part to AKGs. The first clinical studies
using SLOil supplementation were for the treatment of
leukemia and also as a complementary agent administeredto uterine cervix cancer patients submitted to X-ray ther-
apy. In such approaches, SLOil supplementation was able
to avoid leukopenia and thrombocytopenia usually caused
by radiation [21]. There are in vivo studies showing
that SLOil [17] as well as isolated AKGs are able to reduce
tumor growth [18]. Recently, our group showed that
chronic SLOil supplementation was able to reduce tumor
growth and cachexia [22,23], but the action mechanisms
involved in this reduction are not fully understood and
need to be investigated. Moreover, no study has inves-
tigated the effects of a long-term supplementation with
SLOil plus FOil on tumor and cachexia development.
Whereas that FOil is the main source of n-3 PUFAs and
SLOil is the main source of AKGs, the association of both
oils could play an additive effect.
Thus, the aim of this work was to investigate some
mechanisms involved in tumor growth arrest in Walker
256 tumor-bearing rats chronically supplemented with
SLOil, to evaluate the effects on biochemical parameters
of cachexia, and to compare the results with those obtained
from animals supplemented with FOil. Furthermore, it was
investigated if the supplementation with SLOil plus FOil
was able to exert additive effects. To accomplish that,
we determined the tumor weight, ex vivo tumor cell
proliferation rate, lipid peroxidation and apoptosis in
tumor tissue. Body mass, liver glycogen content, serum
concentrations of triacylglycerol, glucose, and lactate have
also been evaluated.
Results
FA composition of tumor tissues was modified by the sup-
plementation protocol (Table 1). In FOil supplemented
animals (WFO and WSLO + FO), the n-3 PUFAs level
in tumor tissues was ~2-fold higher than that in SLOil
supplemented animals and ~4-fold higher when compared
to the W group (p < 0.05). SLOil was able to decrease
the arachidonic acid (AA) concentration in tumor tis-
sues in relation to the W group (p < 0.05); however,
FOil (WFO and WSLO + FO) promoted an even more
significant reduction (p < 0.05).
SLOil was composed by 80% of the main AKG,
octadecenylglycerol, hexadecylglycerol and octadecylglycerol
(Table 2). The tumor tissue of animals supplemented
only with SLOil (WSLO) showed AKG concentration
significantly higher than that in the other groups (p < 0.05)
(Table 3). The main AKGs found in SLOil were ~1.6-fold
higher in WSLO tumors than in W tumors and ~3-fold
in relation to groups supplemented with FOil (WFO and
WSLO+ FO).
Non-tumor-bearing animals gained around 18 g in 2
weeks (Table 4), and oil supplementation did not cause any
further gain. On the other hand, tumor presence caused a
significant loss of body weight in the W animals (~19 g).
SLOil (WSLO) prevented wasting as well as FOil (WFO)
Table 1 Fatty acid profiles of SLOil, FOil, regular chow, and tumor tissue
Fatty acids




W WSLO WFO WSLO + FO
Lauric (12:0) 1.3 ± 0.0 3.2 ± 0.3 1.1 ± 0.0 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
Miristic (14:0) 5.9 ± 0.1 8.7 ± 2.6 - 1.1 ± 0.4 0.7 ± 0.0 1.0 ± 0.2 1.0 ± 0.2
Palmitic (16:0) 34.2 ± 3.7 24.8 ± 2.9 22.3 ± 0.3 24.1 ± 0.9 26.1 ± 2.5 22.8 ± 1.5 26.5 ± 1.5
Palmitoleic (16:1n-7) 4.7 ± 0.4 5.5 ± 0.4 - 2.7 ± 0.1 1.4 ± 0.5 1.7 ± 0.1 1.6 ± 0.2
Stearic (18:0) 2.2 ± 0.1 2.8 ± 0.1 1.9 ± 0.0 15.7 ± 1.9 15.1 ± 0.9 8.0 ± 0.9 9.1 ± 1.4
Oleic (18:1n-9) 29.6 ± 3.1 11.8 ± 0.7 20.4 ± 0.9 24.8 ± 2.6 24.1 ± 3.0 24.8 ± 0.9 25.7 ± 0.9
Linoleic (18:2n-6) 2.1 ± 0.2 2.0 ± 0.5 50.6 ± 3.2 18.5 ± 1.3 22.9 ± 3.1 21.8 ± 2.3 22.6 ± 2.5
α-Linolenic (18:3n-3) 0.3 ± 0.0 0.8 ± 0.0 3.9 ± 0.2 0.5 ± 0.0 0.2 ± 0.0 1.0 ± 0.07 0.9 ± 0.2
Arachidonic (20:4n-6) 1.1 ± 0.1 0.9 ± 0.0 0.1 ± 0.0 16.9 ± 1.3 8.4 ± 2.1a 3.5 ± 0.8a 3.9 ± 1.4a
EPA (20:5n-3) 5.2 ± 0.5 21.3 ± 1.1 - 0.3 ± 0.1 0.6 ± 0.1 1.2 ± 0.2a 0.8 ± 0.2a
DHA (22:6n-3) 11.4 ± 1.0 17.9 ± 1.4 - 1.0 ± 0.0 2.0 ± 0.2 4.2 ± 0.7ab 4.2 ± 0.5ab
Tumor tissue from Walker 256 tumor-bearing rats fed regular chow (W), supplemented with SLOil (WSLO), FOil (WFO) and both (WSLO + FO), determined by HPLC
(high performance liquid chromatography). Data are presented as mean ± SEM of 3 independent measurements (HPLC) of 3 rats per group (n = 9). ap < 0.05
compared to W; bp < 0.05 compared to WSLO.
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ones (CSLO, CFO and CSLO + FO, respectively). The
tumor weight in the W animals was 18.4 ± 1.0 g. The
supplementation with SLOil induced a significant reduction
in the tumor weight, which was 10.9 ± 1.1 g. FOil supple-
mentation caused a more potent effect, and the tumor
weight was 7.3 ± 0.6 g. Both oil supplementations did
not cause any further effect on the tumor weight, similar
to FOil alone (8.2 ± 0.6 g).
Among non-tumor-bearing animals (C, CSLO, CFO,
and CSLO + FO groups), glycemia, triacylglycerolemia,
lactatemia, and liver glycogen content were not different
(p > 0.05) (Table 5). W animals presented reduced glycemia,
hypertriacylglycerolemia, hyperlactatemia, and reduced
liver glycogen content characterizing cachexia state. SLOil
(WSLO) and FOil (WFO) supplementation were able to
keep glycemia and lactatemia levels significantly different
from those of the W group (p < 0.05). The association
of both oils (WSLO + FO) did not cause any further
modification (p > 0.05 vs. WSLO and WFO).
Tumor samples from rats fed with SLOil (WSLO)
showed concentration of lipid hydroperoxides around
1.6-fold greater than those fed with regular chow (W).Table 2 Alkylglycerol composition of SLOil determined
by GC-MS





GC-MS indicates gas chromatography – mass spectrometry.Animals supplemented with FOil (WFO) and those
supplemented with both oils (WSLO + FO) presented
lipid peroxidation ~3-fold higher than tumor samples
from W rats (p < 0.001). WFO tumor samples had a
lipid peroxidation by ~2-fold higher than that from
WSLO group (p < 0.05) (Figure 1).
Supplementation with SLOil (WSLO) promoted re-
duction by ~1.5-fold in the proliferation capacity when
compared to the group fed regular chow (W) (p < 0.001)
(Figure 2). Animals from WFO and WSLO+ FO groups
showed similar reduction of proliferation capacity, i.e., ~2.5-
fold vs. W (p < 0.001) and ~1.5-fold vs. WSLO (p < 0.05).
The analysis of tumor cells by flow cytometry (Table 6)
revealed that SLOil supplementation (WSLO) was able to
increase by ~3-fold the percentage of apoptotic cells, and
reduce by ~2.4-fold the necrotic cells and by ~1.7-fold the
quantity of viable cells in comparison to animals fed regu-
lar chow (W) (p < 0.001). When FOil was applied alone
(WFO) and in association with SLOil (WSLO + FO),
the results obtained were similar, with slight increase
of apoptotic cells percentage in relation to animals
supplemented only with SLOil (p < 0.05).Table 3 Alkylglycerol composition of tumor tissue
Alkylglycerols
(ng/mg of tumor tissue)
Groups
W WSLO WFO WSLO + FO
Hexadecylglycerol (C16:0)+
Octadecylglycerol (C18:0)+ 4.6 ± 0.7 7.6 ± 0.3a 2.8 ± 0.2 2.2 ± 0.3
Octadecenylglycerol (C18:1)
Tumor tissue from Walker 256 tumor-bearing rats fed regular chow (W),
supplemented with SLOil (WSLO), FOil (WFO) or both (WSLO + FO), determined
by GC-MS (gas chromatography – mass spectrometry). Data are presented as
mean ± SEM of 3 independent measurements (GC-MS) of 3 rats per group
(n = 9). ap < 0.05 compared to other groups.
Table 4 Body, tumor and carcass weight of non-tumor bearing rats (prefix C), and Walker 256 tumor-bearing rats (prefix W)
Group Body weight before
tumor inoculation (g)
Body weight 14 days
after inoculation (g)
Tumor weight





C 322.3 ± 17.5 338.4 ± 16.8 - - +16.2 ± 2.0
CSLO 317.4 ± 13.5 336.5 ± 12.2 - - +17.9 ± 3.9
CFO 316.8 ± 7.8 334.4 ± 7.2 - - +17.7 ± 2.1
CSLO + FO 331.5 ± 7.0 351.1 ± 7.7 - - +19.6 ± 2.3
W 321.3 ± 17.3 319.0 ± 11.9 18.4 ± 1.0 301.5 ± 11.6 −18.5 ± 1.4b
WSLO 320.1 ± 6.7 348.8 ± 7.9 10.9 ± 1.1a 337.9 ± 7.1 +12.9 ± 2.5a
WFO 317.3 ± 11.6 338.3 ± 8.8 7.3 ± 0.6ac 331.1 ± 8.7 +15.5 ± 0.9a
WSLO + FO 327.0 ± 9.6 349.4 ± 12.6 8.2 ± 0.6a 340.9 ± 13.2a +18.5 ± 1.9a
Rats fed regular chow (C and W), supplemented with SLOil (CSLO and WSLO), FOil (CFO and WFO) and both (CSLO + FO and WSLO + FO). Data are presented as
mean ± SEM of 4 independent experiments of 5 rats per group (n = 20). ap < 0.05 compared to W; bp < 0.01 compared to C; cp < 0.01 compared to WSLO.
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The role of diet in cancer development has been extensively
studied in the last years [1,4-7,12,15]. It has been advocated
that 30–40% of cancers may be prevented by appropriated
diets, physical activity, and maintenance of body weight
[24]. The 256 Walker tumor is a good tool to study
cachexia. All the features presented in the W group are
commonly seen in cachectic individual [6,25].
The group supplemented with FOil only has been
taken in this work as a reference point to compare with
SLOil effects. The reduction of about 60% in the tumor
weight of the WFO group has been reported in previous
studies that used the same experimental model [6,7]. FOil
supplementation was able to maintain body weight and
metabolic parameters in the tumor-bearing rats (WFO) to
similar values when compared to the non-tumor-bearing
group (CFO). These results are in agreement with those
obtained by other studies with animal models [6,10,25].Table 5 Serum concentrations of glucose, triacylglycerol
(TAG) and lactate, and liver glycogen content of











C 97.4 ± 3.2 67.4 ± 3.4 1.28 ± 0.1 137.5 ± 5.9
CSLO 96.8 ± 2.2 71.8 ± 3.8 1.27 ± 0.1 137.7 ± 5.5
CFO 98.7 ± 3.3 63.2 ± 6.1 1.39 ± 0.1 156.8 ± 7.2
CSLO + FO 94.9 ± 2.3 66.9 ± 3.2 1.27 ± 0.1 148.5 ± 8.4
W 78.7 ± 1.5a 113.4 ± 9.4a 2.26 ± 0.1a 94.5 ± 9.8a
WSLO 87.9 ± 2.5b 92.3 ± 4.4 1.47 ± 0.1b 124.7 ± 2.3b
WFO 99.9 ± 3.9b 78.9 ± 4.7b 1.5 ± 0.1b 125.2 ± 5.6ab
WSLO + FO 94.4 ± 2.3b 83.8 ± 4.6b 1.43 ± 0.1b 125.4 ± 3.5ab
Rats fed regular chow (C and W), supplemented with SLOil (CSLO and WSLO),
FOil (CFO and WFO) and both (CSLO + FO and WSLO + FO). Data are presented
as mean ± SEM of 4 independent experiments of 5 rats per group (n = 20).
ap < 0.01 compared to respective group without tumor; bp < 0.05 compared to
W group.Supplementation with SLOil also reduced tumor growth
by ~40%, as showed in a previous study of our group [23].
Although the tumor-bearing rats (SLOil supplemented)
have tumor size ~30% bigger than FOil supplemented rats,
they completely reversed the cachexia state. Some studies
have suggested that cachexia in Walker 256 tumor-bearing
rats is directly connected to tumor size [10,25]. However, as
we have reported in a previous study [6], here we show that
such association is not always present. More important is
that FOil and SLOil have similar efficient anti-cachectic
properties in this model.
The capsules of the SLOil and FOil used in the present
study contain EPA and DHA (Table 1). However, in
addition to n-3 PUFAs, the SLOil capsules used here
are rich in AKGs (Table 2), which are not found in FOil
and regular rodent chow. Pédrono et al. [18] showed
that AKGs purified from SLOil and the whole oil
supplemented orally to animals reduced tumor growth
similarly, indicating that anti-tumor activity of SLOil is
probably due to AKG. AKG can be inserted in the cellFigure 1 Lipid hydroperoxide concentration in tumor tissue.
Tumors from animals fed regular chow (W), supplemented with SLOil
(WSLO), FOil (WFO) and both (WSLO + FO). Values are mean ± SEM of 3
independent assays; 8 (W) (n = 24), 6 (WSLO) (n = 18), 6 (WFO) (n = 18)
and 5 (WSLO + FO) (n = 15) rats. ap < 0.001 compared to W; bp < 0.05
compared to WSLO.
Figure 2 Ex vivo proliferation rate (counts/min) of 256 Walker
tumor cells. Tumors from animals fed regular chow (W), and
supplemented with SLOil (WSLO), FOil (WFO) and both (WSLO + FO).
Data are presented as mean ± SEM of 3 independent assays of 10
rats per group (n = 30). ap < 0.001 compared to W, bp < 0.05
compared to WSLO.
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for the formation of second messengers with ether linkage,
which can interfere with the activity of enzymes involved
in the control of cell proliferation and differentiation, such
as protein kinase C (PKC) [20,26,27]. The anti-tumor effect
of SLOil has been associated to the interaction of 1-O-alkyl-
2-acylglycerol, an analogue of diacylglycerol (DAG), with
PKC [28]. In addition, studies with cultured cells suggest
that ether phospholipids, such as n-3 fatty acids, can be ac-
cumulated in lipid rafts and act on cell-signaling by affect-
ing the protein composition of these microdomains [29].
SLOil contains n-3 PUFAs and AKGs in its composition,
and it cannot be discarded that tumor and cachexia reduc-
tion in WSLO animals may be the result of the combined
action of both compounds. It has been known that n-3
PUFAs have the ability to decrease production of tumor
factors involved in the promotion of cachexia [2], and this
fact may have contributed to the reduction of cachexia
in animals supplemented with FOil (WFO) and SLOil
(WSLO). However, SLOil has only half the concentration of
n-3 PUFAs than FOil, so AKG also may exert active effectTable 6 Percentage of apoptotic, necrotic and viable cells
of 256 Walker tumors
Groups Apoptotic cells (%) Necrotic cells (%) Viable cells (%)
W 19.8 ± 2.3 30.6 ± 1.1 49.6 ± 2.7
WSLO 56.9 ± 1.0a 12.8 ± 1.2a 28.9 ± 1.5a
WFO 68.5 ± 2.9ab 7.5 ± 0.9ab 23.7 ± 1.0a
WSLO + FO 64.8 ± 0.6ab 13.5 ± 0.5a 21.6 ± 0.7ab
Values determined by FACS (fluorescence-activated cell sorting), from animals
fed regular regular chow (W), and supplemented with SLOil (WSLO), FOil
(WFO), and both (WSLO + FO). Data are presented as mean ± SEM of 4
independent experiments of 5 rats per group (n = 20). ap < 0,05 compared to
W; bp < 0,05 compared to WSLO.upon cachexia. Therefore, the mechanisms related to the
effects of these ether lipids need to be further investigated.
The results obtained to EPA and DHA concentrations in
the WSLO and WFO tumor tissues (~2.6% and ~5.4%, re-
spectively; Table 1) are in agreement with n-3 PUFA content
in SLOil and FOil capsules (~17% and ~39%, respectively).
The WSLO tumor tissue showed half the percentage of
AA in relation to W group, while WFO showed about
4-fold less AA than W group. Elevated concentrations
of AA in tumor tissue are related to high prostaglandin E2
(PGE2) production by tumor, and, consequently, enhanced
tumor development [7].
N-3 PUFAs are very susceptible to peroxidation, which
explains the higher concentration of lipid hydroperoxides
(~2-fold) found in tumors from the WFO group than
those found in WSLO tumors (Figure 1). Peroxidation
products are able to inhibit tumor growth by increasing
apoptosis, contributing to antiproliferative effect of these
compounds [30,31]. Indeed, results obtained by FACS
showed that independent supplementation with SLOil and
FOil promoted increase in apoptosis in relation to group
W (Table 6). However, SLOil promoted slightly lower
tumor cell apoptosis than FOil, even though half the
concentration of n-3 PUFAs has been found in tumor
tissue. A small difference also can be observed in the
percentage of viable cells between the WSLO and WFO
groups. Thus, it can be suggested that part of the pro-
apoptotic effect may be attributed to AKGs from SLOil.
Indeed, the concentration of AKGs in the WSLO tumor
tissue has been around 3-fold greater than that found in
WFO (Table 2). The proliferation capacity of tumor cells
from the WSLO group was significantly reduced in relation
to the W group (~1.5-fold), but the WFO group presented
even bigger reductions (~2.4-fold; almost 50% lower than
WSLO) (Figure 2). Although FOil has been more effective
in reducing tumor cell proliferation, SLOil chronic inges-
tion showed important capacity to control tumor growth
directly. The indirect anti-tumor action of SLOil by the
stimulation of the immune system has not been studied
here, but recently, our group found that the long-life ex-
posure to SLOil was able to increase the nitrite production
by the peritoneal macrophages. The nitrite production is
indicative of NO production, and NO could contribute to
the reduction of tumor growth in WSLO animals [22].
Contrary to our expectations, the association of SLOil
and FOil (WSLO+ FO group) did not cause additive effects
on tumor growth reduction as well as in the cachexia
parameters (Tables 4 and 5). Lipid hydroperoxide content
in tumor tissues from WSLO+ FO animals was not sig-
nificantly different from those observed in WFO animals
(Figure 1). In the same way, tumor cell proliferation
capacity and percentage of apoptotic cells were similar
in both groups (Figure 2 and Table 6, respectively). These
results suggest that FOil is the main factor, and SLOil did
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the WSLO+ FO group showed similar proportion of n-3
PUFAs, EPA, and DHA (Table 1) when compared to
WFO and approximately twice the concentration found in
WSLO tumors. Interestingly, the concentration of AKGs
in the WFO and WSLO+ FO groups was also similar and
about 3-fold lower than that found in the WSLO group
(Table 3). These results suggest that the incorporation of
AKGs in tumor cells is reduced when there is another sup-
ply of fat in the diet. We suggest that when FOil, rich in n-3
PUFAs, and SLOil, rich in AKG, are applied together, n-3
PUFAs are preferentially incorporated into the tumor tissue,
and the incorporation of AKG is significant only when
SLOil is offered alone. This competition for incorporation
into the lipid bilayer may help to explain why the effects on
tumor growth, lipid peroxidation, proliferation capacity of
tumor cell, apoptosis, and cachexia parameters observed in
the WFO and WSLO+ FO groups were identical.
Conclusions
Here we show that independent chronic ingestion of
SLOil is able to reduce Walker 256 tumor growth, and
this effect is linked to increased lipid peroxidation, in-
creased apoptosis, and reduced tumor cell proliferative
capacity. Although FOil supplementation has been more
effective to reduce tumor growth, SLOil and FOil showed
equivalent anti-cachectic properties. Association of SLOil
and FOil did not cause additive effect on tumor growth or
cachexia and produced results similar to those found in
animals supplemented with FOil alone, probably because
of competition between n-3 PUFA and AKG for incorpor-
ation in the tumor cell membrane.
Methods
Study design
Procedures involving animals were approved by the
Committee of Animal Welfare of the Federal University of
Paraná. Weanling male Wistar rats (age, 21 days) were
maintained under controlled temperature (23°C) and
humidity in 12-h light/12-h dark cycle and randomized
into 4 dietary groups. The control group (C) received a
regular chow (protein content, 230 g/kg; fiber, 60 g/kg; fats,
40 g/kg; carbohydrates, 660 g/kg; vitamins and minerals,
10 g/kg; Nuvital CR-1; Curitiba, PR, Brazil). Three groups
received, in addition to regular chow, daily fat supplemen-
tation (1 g/kg body weight) as follows: SLOil (CSLO), FOil
(CFO), and SLOil + FOil (CSLO+ FO, 1 g/kg body weight
of each oil). After 8 weeks, 50% of the rats were inoculated
subcutaneously in the right flank with 1 mL of a sterile
suspension of 3 × 107 Walker tumor cells that were
obtained from an ascitic tumor-bearing rat. Walker
256 tumor-bearing groups were identified by the prefix
W (W, WSLO, WFO, and WSLO+ FO). Supplementation
continued to be made for additional 2 weeks after tumorinoculation. Body weight was monitored every 2 days. Four-
teen days after tumor inoculation, animals were killed by
decapitation without anesthesia. The tumors were removed,
weighed, and the samples were reserved for assays. Blood
was collected into 15 mL tubes and allowed to clot for
30 min at room temperature. Serum was prepared by centri-
fugation and used for the measurement of lactate, glucose,
and triacylglycerol concentrations. Liver pieces were excised
and frozen to posterior glycogen content detection.
Chemicals, oils, and enzymes
Chemicals and enzymes used in this study were
obtained from Sigma Chemical Co. (St. Louis, MO, USA).
Biochemical kits were obtained from BioLiquid® (Laborclin;
Pinhais, PR, Brazil). FOil from Herbarium® and SLOil from
Ecomer® were kindly donated by the Herbarium Foundation
(Curitiba, PR, Brazil) and the Naturalis Alimentos Naturais
Ltda (São Paulo, SP, Brazil), respectively.
Biochemical parameters of cachexia
Serum lactate (mmol/L), glucose (mg/dL), and triacylglycerol
(mg/dL) were analyzed immediately after the animals
were killed. Liver was frozen in liquid nitrogen to poster-
ior glycogen measurement. For the lactate assay, serum
(0.5 mL) was added to 0.1 mL of perchloric acid (25%)
and left for 10 min at 4°C followed by centrifugation at
3,000 g for 5 min. The supernatant was collected and
neutralized with Tris/KOH (2 M/0.5 M), and the con-
centration of lactate was enzimatically determined as
previously described [32] at 340 nm. Serum glucose
and triacylglycerol measurements were performed with
enzimatically colorimetric commercial BioLiquid® kits
and quantified by measuring the absorbance at 505 nm and
540 nm, respectively. For the glycogen assay, accurately
weighed pieces of liver (0.07 g) were put into 0.5 mL of
KOH aqueous solution (1 mol/L) and left for 20 min at
70°C for tissue digestion. After that, a digested sample
(0.1 mL) was added to 0.5 mL triethanolamine buffer
containing amyloglucosidase and incubated for 2 h at
room temperature. After centrifugation (800 g for 5 min),
the supernatant (0.2 mL) was added to 1 mL of glucose
assay buffer as previously described [33]. Glycogen was
quantified by measuring the absorbance at 340 nm, and
the calculated results were expressed as μmol/g of tissue
(w/w). Data are presented as mean ± SEM of 4 independent
measurements, 5 rats per group (n = 20).
Determination of fatty acids (FAs) by using HPLC and
AKGs by using GC-MS
The lipids were extracted [34] from standard commercial
chow, SLOil, FOil, and tumor tissue (3 independent mea-
surements, 3 rats per group, n = 9) and saponified by using
2 mL of an alkaline methanol solution (1 mol NaOH/L in
90% methanol) at 37°C for 2 h in a shaking water bath.
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HCl solution (1 mol/L). FAs were then extracted 3 times
with 2 mL hexane. After the extraction procedure and
saponification [35,36], the FAs were derivatized with
4-bromomethyl-7 methoxycoumarim [37], and the ana-
lysis was performed on a Varian model LC-10A liquid
chromatograph. The samples were placed on a C8 column
(25 cm× 4.6 mm i.d.; 5 μm of particles) with a flow rate of
1 mL/min of acetonitrile/water (77:23, v/v) and a fluores-
cence detector (325 nm excitation and 395 nm emission).
The standard mixture of FA was obtained from Sigma
Chemical Co. (St. Louis, MO, USA). The elution sequence
and limit of detection were determined. The minimum
limit of quantification of the FAs ranged from 1–10 ng.
One curve of calibration for each standard, determining the
coefficients of correlation and regression, was obtained.
The AKG profile was determined by using GC-MS
(gas chromatography–mass spectrometry) as follows: Total
lipids were extracted from SLOil capsules and tumor tissue
using chloroform-methanol (2:1 v/v) [34]. Then, the content
was hydrolyzed and kept under 100°C for 2 h. The samples
were dried out under nitrogen gas and added 0.2 mL of
ethanoyl ethanoate and 0.2 mL of pyridine followed by 30
min of incubation at 100°C [38]. AKGs were separated on a
GC-MS Saturn 2000R by using a CP-Sil-5 CB Chrompack®
column (30 m× 0.25 mm). The results are presented as ng
of AKG per mg of tumor tissue. An external standard
galactitol, 48 ng/μL by injection was used for this assay.
SLOil was composed of 50 mg of AKG/250 mg of oil.
Tumor tissue lipid hydroperoxides
The products of peroxidation were measured using the
method previously described [39]. Tumor tissue (0.2 mg)
was homogenized in methanol (1 mL) and centrifuged,
and 90 μL of the supernatant was added to the reac-
tion tubes containing 10 μL of methanol or 10 μL of
triphenylphosphine (10 mM). Thereafter, was added 0.9 mL
of reaction solution (100 μM xylenol orange, 250 μM Fe+2,
25 mM H2SO4, and 4 mM butylated hydroxytoluene in
90% (v/v) methanol) and incubated for 30 min at room
temperature prior to measurement at 560 nm. The concen-
tration of lipid hydroperoxides was calculated by subtracting
the absorbance of tryphenylphosphine samples from respect-
ive methanol samples, and values were expressed as nmol of
lipid hydroperoxides/mg of protein. The protein content of
the tumor tissue homogenates was measured by using the
Bradford method [40], using bovine serum albumin (BSA)
as the standard. Data are presented as mean ± SEM of 3
independent assays; 8 (W) (n = 24), 6 (WSLO) (n = 18),
6 (WFO) (n = 18) and 5 (WSLO + FO) (n = 15) rats.
Ex vivo Walker 256 tumor cell proliferation
The whole tumor was removed and chopped with a scalpel.
The cell suspension was obtained by filtration throughfunnel and gauze. Red blood cells were discharged with
a solution containing NH4CL (15.5 mM). Tumor cells
were prepared by centrifugation at 290 g for 7 min and were
resuspended in RPMI 1640 medium. Tumor cells were
cultured for 24 h at 37°C in an air/CO2 (19:1) atmosphere
in 96-well microtiter-culture plates at a density of 1 × 105
cells/well in RPMI 1640 medium enriched with 10% fetal
calf serum containing 100 U/mL penicillin and 100 μg/mL
streptomycin (Gibco; Grand Island, NY) and 0.05 μCi of
[2-14C]-thymidine. The cells were harvested onto glass
fiber disks (Filtermats; COX Scientific Ltd., Kettering, UK)
and washed using a Titertek Cell Harvester (Skattron,
Lier, Norway). Radioactive thymidine incorporation into
DNA was determined by liquid scintillation counting in
a Beckman LS 6000IC scintillation counter [33]. Results
are presented as counts per minute (cpm)/105 cells, of 3
independent assays, 10 rats per group (n = 30).
Tumor cell flow cytometry analysis
The percentage of tumor cells undergoing apoptosis
and necrosis was evaluated by using annexin V-FITC
(fluorescein isothiocyanate; Produced by Institute of
Biomedical Sciences, University of São Paulo, Brazil)
and 7-AAD (7-amino-actinomycin D; BD Biosciences
Pharmingen), respectively. Tumor cells (106), isolated
from tumors after tumor extraction, were stained with
annexin V-FITC for 15 min and with 7-AAD for 5 min and
then analyzed using flow cytometry (FACS – fluorescence-
activated cell sorting). The fluorescence was analyzed using
flow cytometer FACScalibur (Becton Dickinson; San Jose,
CA). The tumor cell population was primarily selected from
the forward-scattered light (FSC) vs. side-scattered light
(SSC) dot plot in linear mode. Then, a FL1 vs. FL3 dot plot
in log mode was constructed to quantify cells labeled with
annexin V-FITC (FL1, low right quadrant) and cells labeled
with 7-AAD (FL3, up left quadrant). Cells that were located
in the low left quadrant (not labeled cells) were considered
viable. The cells positive for annexin V-FITC were consid-
ered to be in an early stage of apoptosis. Data are presented
as mean ± SEM of 4 independent measurements of 5 rats
per group (n = 20).
Statistical analysis
Data are presented as mean ± standard error of mean
(SEM). Statistical analysis were performed by unpaired
t-test and one-way analysis of variance (ANOVA) followed
by a post hoc Tukey test, when diet or tumor was used as a
factor. Data were analyzed using GraphPad prism software
(version 5.0; GraphPad Software; San Diego, California).
P < 0.05 was taken to indicate statistical significance.
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